- Dr. Paul Kessler Appointed to Position -
BOCA RATON, Fla., Feb. 16 /PRNewswire-FirstCall/ -- Nabi
Biopharmaceuticals (Nasdaq: NABI) announced today that Henrik S. Rasmussen,
M.D., Ph.D., has decided to resign his position as the company's senior
vice president, clinical, medical and regulatory affairs. Dr. Rasmussen is
leaving the company to accept a position with expanded responsibilities
with Novo Nordisk. His decision to accept the position was made prior to
and is unrelated to the announcement yesterday of the resignation of Thomas
H. McLain as chairman, chief executive officer and president of Nabi
Biopharmaceuticals.
Dr. Rasmussen will remain with the company until March 2, 2007 to
assist in transitional activities. The company has named Paul Kessler,
M.D., as its new senior vice president, clinical, medical and regulatory
affairs. Dr. Kessler currently serves as vice president, clinical and
medical research for Nabi Biopharmaceuticals and has been with the company
since 2005. Dr. Kessler has a BS from University of Pittsburgh, a Masters
in Science from University of London in London, England and his M.D. from
Columbia University in New York City. He was formerly Head of Clinical
Research and Regulatory Affairs at Gen Vec Inc. in Gaithersburg, Maryland.
"I and the board of directors would like to thank Henrik for his
countless contributions on behalf of Nabi Biopharmaceuticals," said Dr.
Leslie Hudson, interim chief executive officer and president, Nabi
Biopharmaceuticals. "Thanks in large part to Henrik's tireless efforts,
Nabi Biopharmaceuticals has successfully advanced forward a deep pipeline
of commercially promising product candidates with the potential to improve
treatment outcomes for patients and to build value for our shareholders.
While Henrik's contributions will be missed, we are happy that his new
position will afford him the opportunity to travel to Denmark and spend
more time with his extended family. We wish him the best of luck in all his
future endeavors."
About Nabi Biopharmaceuticals
Nabi Biopharmaceuticals leverages its experience and knowledge in
powering the immune system to develop and market products that fight
serious medical conditions. The company has two products on the market
today: Nabi-HB(R) [Hepatitis B Immune Globulin (Human)], and Aloprim(TM)
(allopurinol sodium) for Injection. Nabi Biopharmaceuticals is focused on
developing products that address unmet medical needs and offer commercial
opportunities in our core business areas: Hepatitis and transplant,
Gram-positive bacterial infections and nicotine addiction. For a complete
list of pipeline products, please go to:
http://www.nabi.com/pipeline/index.php. The company is headquartered in
Boca Raton, Florida. For additional information about Nabi
Biopharmaceuticals, please visit our website at http://www.nabi.com.
Forward-Looking Statements
Statements in this press release about the company that are not
strictly historical are forward-looking statements and include statements
related to our plans to explore strategic alternatives and prospects. You
can identify these forward-looking statements because they involve our
expectations, beliefs, intentions, plans, projections, or other
characterizations of future events or circumstances. These forward-looking
statements are not guarantees of future performance and are subject to
risks and uncertainties that may cause actual results to differ materially
from those in the forward-looking statements as a result of any number of
factors. These factors include, but are not limited to, risks relating to
the company's ability to advance the development of products currently in
the pipeline or in clinical trials; maintain the human and financial
resources to commercialize current products and bring to market products in
development; obtain regulatory approval for its products in the U.S.,
Europe or other markets; successfully develop, manufacture and market its
products; successfully partner with other companies; realize future sales
growth for its biopharmaceutical products; maintain sufficient intellectual
property protection or positions; raise additional capital on acceptable
terms; re-pay its outstanding convertible senior notes when due; and
identify and complete transactions that represent strategic alternatives
and opportunities. Many of these factors are more fully discussed, as are
other factors, in the company's Annual Report on Form 10-K for the fiscal
year ended December 31, 2005 and Quarterly Report on Form 10-Q for the
Quarter ended September 30, 2006 filed with the Securities and Exchange
Commission.
SOURCE Nabi Biopharmaceuticals
 back to top
Related links:
http://www.nabi.com
http://www.nabi.com/pipeline/index.php/
CONTACT:
Thomas E. Rathjen, Vice President, Investor
Relations, of Nabi Biopharmaceuticals, +1-561-989-5800
|
